Effect of atractylone on the viability and apoptosis of hepatoma HepG2 cells and related mechanism

ObjectiveTo investigate the effect of atractylone on the viability and apoptosis of hepatoma HepG2 cells and its mechanism of action. MethodsHepatoma HepG2 cells were selected and divided into low-, middle-, and high-dose atractylone groups (5, 10, and 20 μmol/L), and the cells in the control group...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autor principal:	YANG Xueli
Formato:	article
Lenguaje:	ZH
Publicado:	Editorial Department of Journal of Clinical Hepatology 2021
Materias:	Diseases of the digestive system. Gastroenterology RC799-869
Acceso en línea:	https://doaj.org/article/146858d810a9433fbb2880e8166009fa
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:146858d810a9433fbb2880e8166009fa
record_format	dspace
spelling	oai:doaj.org-article:146858d810a9433fbb2880e8166009fa2021-11-17T10:57:57ZEffect of atractylone on the viability and apoptosis of hepatoma HepG2 cells and related mechanism1001-5256https://doaj.org/article/146858d810a9433fbb2880e8166009fa2021-11-01T00:00:00Zhttp://www.lcgdbzz.org/cn/article/doi/10.3969/j.issn.1001-5256.2021.11.020https://doaj.org/toc/1001-5256ObjectiveTo investigate the effect of atractylone on the viability and apoptosis of hepatoma HepG2 cells and its mechanism of action. MethodsHepatoma HepG2 cells were selected and divided into low-, middle-, and high-dose atractylone groups (5, 10, and 20 μmol/L), and the cells in the control group were added with an equal volume of DMSO. MTT colorimetry was used to measure the viability of HepG2 cells after treatment with different concentrations of atractylone; flow cytometry was used to measure the apoptosis rate and mitochondrial membrane potential of HepG2 cells; the DCFH-DA fluorescent probe labeling method was used to measure the level of reactive oxygen species (ROS) in HepG2 cells; Transwell assay was used to evaluate the effect of atractylone on the migration ability of HepG2 cells; Western blot was used to measure the protein expression levels of Bcl-2, Bax, and cleaved caspase-3. A one-way analysis of variance was used for comparison of continuous data between multiple groups, and the least significant difference t-test was used for comparison between two groups. ResultsAfter 24 and 48 hours of treatment with atractylone, compared with the control group, the low-, middle-, and high-dose atractylone groups had a tendency of reduction in cell viability (all P＜0.05), with a half inhibitory concentration of 26.19 μmol/L in atractylone treatment of HepG2 cells for 72 hours. The low-, middle-, and high-dose atractylone groups had a significantly higher apoptosis rate than the control group (14.34%/29.32%/50.12% vs 0.32%, all P＜0.05). Compared with the control group, the low-, middle-, and high-dose atractylone groups had a significant increase in the fluorescence intensity of ROS in HepG2 cells (all P＜0.05). After 48 hours of treatment with atractylone, compared with the control group, the low-, middle-, and high-dose atractylone groups had a significant reduction in the number of migrated cells (132.67±18.36/57.00±9.26/31.00±2.45 vs 258.11±38.54, P＜0.05). Compared with the control group, the low-, middle-, and high-dose atractylone groups had a significant reduction in the expression of the anti-apoptotic factor Bcl-2 and significant increases in the expression of the apoptotic factors Bax and cleaved caspase-3 (all P＜0.05). ConclusionAtractylone can induce the apoptosis and inhibit the migration of HepG2 cells, which provides an experimental basis for further development and utilization of atractylone.YANG XueliEditorial Department of Journal of Clinical HepatologyarticleDiseases of the digestive system. GastroenterologyRC799-869ZHLinchuang Gandanbing Zazhi, Vol 37, Iss 11, Pp 2589-2594 (2021)
institution	DOAJ
collection	DOAJ
language	ZH
topic	Diseases of the digestive system. Gastroenterology RC799-869
spellingShingle	Diseases of the digestive system. Gastroenterology RC799-869 YANG Xueli Effect of atractylone on the viability and apoptosis of hepatoma HepG2 cells and related mechanism
description	ObjectiveTo investigate the effect of atractylone on the viability and apoptosis of hepatoma HepG2 cells and its mechanism of action. MethodsHepatoma HepG2 cells were selected and divided into low-, middle-, and high-dose atractylone groups (5, 10, and 20 μmol/L), and the cells in the control group were added with an equal volume of DMSO. MTT colorimetry was used to measure the viability of HepG2 cells after treatment with different concentrations of atractylone; flow cytometry was used to measure the apoptosis rate and mitochondrial membrane potential of HepG2 cells; the DCFH-DA fluorescent probe labeling method was used to measure the level of reactive oxygen species (ROS) in HepG2 cells; Transwell assay was used to evaluate the effect of atractylone on the migration ability of HepG2 cells; Western blot was used to measure the protein expression levels of Bcl-2, Bax, and cleaved caspase-3. A one-way analysis of variance was used for comparison of continuous data between multiple groups, and the least significant difference t-test was used for comparison between two groups. ResultsAfter 24 and 48 hours of treatment with atractylone, compared with the control group, the low-, middle-, and high-dose atractylone groups had a tendency of reduction in cell viability (all P＜0.05), with a half inhibitory concentration of 26.19 μmol/L in atractylone treatment of HepG2 cells for 72 hours. The low-, middle-, and high-dose atractylone groups had a significantly higher apoptosis rate than the control group (14.34%/29.32%/50.12% vs 0.32%, all P＜0.05). Compared with the control group, the low-, middle-, and high-dose atractylone groups had a significant increase in the fluorescence intensity of ROS in HepG2 cells (all P＜0.05). After 48 hours of treatment with atractylone, compared with the control group, the low-, middle-, and high-dose atractylone groups had a significant reduction in the number of migrated cells (132.67±18.36/57.00±9.26/31.00±2.45 vs 258.11±38.54, P＜0.05). Compared with the control group, the low-, middle-, and high-dose atractylone groups had a significant reduction in the expression of the anti-apoptotic factor Bcl-2 and significant increases in the expression of the apoptotic factors Bax and cleaved caspase-3 (all P＜0.05). ConclusionAtractylone can induce the apoptosis and inhibit the migration of HepG2 cells, which provides an experimental basis for further development and utilization of atractylone.
format	article
author	YANG Xueli
author_facet	YANG Xueli
author_sort	YANG Xueli
title	Effect of atractylone on the viability and apoptosis of hepatoma HepG2 cells and related mechanism
title_short	Effect of atractylone on the viability and apoptosis of hepatoma HepG2 cells and related mechanism
title_full	Effect of atractylone on the viability and apoptosis of hepatoma HepG2 cells and related mechanism
title_fullStr	Effect of atractylone on the viability and apoptosis of hepatoma HepG2 cells and related mechanism
title_full_unstemmed	Effect of atractylone on the viability and apoptosis of hepatoma HepG2 cells and related mechanism
title_sort	effect of atractylone on the viability and apoptosis of hepatoma hepg2 cells and related mechanism
publisher	Editorial Department of Journal of Clinical Hepatology
publishDate	2021
url	https://doaj.org/article/146858d810a9433fbb2880e8166009fa
work_keys_str_mv	AT yangxueli effectofatractyloneontheviabilityandapoptosisofhepatomahepg2cellsandrelatedmechanism
_version_	1718425591927013376

Effect of atractylone on the viability and apoptosis of hepatoma HepG2 cells and related mechanism

Ejemplares similares